Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents
MetadataShow full item record
Herrera Ibatá D.M.
The frequency, complexity and morbidity of neurodegenerative diseases make them a great challenge for nowadays medicine. Most of the treatments currently used for Parkinson's disease – the second most prevalent – are only symptomatic. Therefore, it is urgent to develop drugs that are able to act simultaneously on different targets, being able to stop neuronal death and promote the recovery of neuronal populations already affected. In this work, we studied the activity of a series of hybrid molecules, which combine the structure of both coumarin and an alkynylamine group inspired on rasagiline, as MAO inhibitors, antioxidants and neuroprotective agents. Half of the studied hybrids turned out to be selective monoamine oxidase B (hMAO-B) inhibitors in the low micro/nanomolar range, demonstrating that positions 3 (compounds 1–3) and 7 (compounds 8 and 10) of the coumarin scaffold are the most suitable for the incorporation of the alkynylamine chain. All the studied compounds proved to be capable of neutralizing free radicals (DPPH). Finally, the 4-(but-2-yn-1-ylamino)coumarin (5) showed neuroprotective effects on glial cells and the 4-methyl-7-(pent-2-yn-1-ylamino)coumarin (8) inhibited intraneuronal ROS production as well. © 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Showing items related by title, author, creator and subject.
Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson's disease: Synthesis, in vitro and in vivo studies (2020) Rodríguez-Enríquez F.; Viña D.; Uriarte E.; Fontenla J.A.; Matos M.J. (Academic Press Inc., 2020)
3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter? (2020) Mellado M.; Mella J.; González C.; Viña D.; Uriarte E.; Matos M.J. (Academic Press Inc., 2020)
Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors (2020) Morales-Camilo N.; Salas C.O.; Sanhueza C.; Espinosa-Bustos C.; Sepúlveda-Boza S.; Reyes-Parada M.; Gonzalez-Nilo F.; Caroli-Rezende M.; Fierro A. (Blackwell Publishing Ltd, 2015)